Cargando…
Multiple Sclerosis, COVID-19 and Vaccines: Making the Point
On 11 March 2020, the World Health Organization declared the coronavirus disease 19 (COVID-19) outbreak a pandemic. In this context, several studies and clinical trials have been conducted since then, and many are currently ongoing, leading to the development of several COVID-19 vaccines with differ...
Autores principales: | Toscano, Simona, Chisari, Clara G., Patti, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500471/ https://www.ncbi.nlm.nih.gov/pubmed/34625925 http://dx.doi.org/10.1007/s40120-021-00288-7 |
Ejemplares similares
-
Rituximab for the treatment of multiple sclerosis: a review
por: Chisari, Clara Grazia, et al.
Publicado: (2021) -
Reliability of televisits for patients with mild relapsing–remitting multiple sclerosis in the COVID-19 era
por: Toscano, Simona, et al.
Publicado: (2022) -
Correction to: Reliability of televisits for patients with mild relapsing–remitting multiple sclerosis in the COVID‑19 era
por: Toscano, Simona, et al.
Publicado: (2022) -
Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature
por: Patti, Francesco, et al.
Publicado: (2022) -
Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
por: Chisari, Clara G., et al.
Publicado: (2021)